Atrial fibrillation in horses Part 2: Diagnosis, treatment and prognosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Atrial fibrillation in horses Part 2 : Diagnosis, treatment and prognosis. / Decloedt, Annelies; Van Steenkiste, Glenn; Vera, Lisse; Buhl, Rikke; van Loon, Gunther.

I: Veterinary Journal, Bind 268, 105594, 2021.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Decloedt, A, Van Steenkiste, G, Vera, L, Buhl, R & van Loon, G 2021, 'Atrial fibrillation in horses Part 2: Diagnosis, treatment and prognosis', Veterinary Journal, bind 268, 105594. https://doi.org/10.1016/j.tvjl.2020.105594

APA

Decloedt, A., Van Steenkiste, G., Vera, L., Buhl, R., & van Loon, G. (2021). Atrial fibrillation in horses Part 2: Diagnosis, treatment and prognosis. Veterinary Journal, 268, [105594]. https://doi.org/10.1016/j.tvjl.2020.105594

Vancouver

Decloedt A, Van Steenkiste G, Vera L, Buhl R, van Loon G. Atrial fibrillation in horses Part 2: Diagnosis, treatment and prognosis. Veterinary Journal. 2021;268. 105594. https://doi.org/10.1016/j.tvjl.2020.105594

Author

Decloedt, Annelies ; Van Steenkiste, Glenn ; Vera, Lisse ; Buhl, Rikke ; van Loon, Gunther. / Atrial fibrillation in horses Part 2 : Diagnosis, treatment and prognosis. I: Veterinary Journal. 2021 ; Bind 268.

Bibtex

@article{431e4b4820e645d2aaae747788eba297,
title = "Atrial fibrillation in horses Part 2: Diagnosis, treatment and prognosis",
abstract = "Atrial fibrillation (AF) is suspected by an irregularly irregular rhythm during auscultation at rest and should be confirmed by electrocardiography. Heart rate monitoring is potentially interesting for AF detection by horse owners, based on the disproportionally high heart rate during exercise or increased heart rate variability. Echocardiography and laboratory analysis are useful to identify underlying cardiac disease. Horses with severe cardiac disease should not undergo cardioversion due to the risk of recurrence. Cardioversion is recommended especially in horses performing high intensity exercise or showing average maximal heart rates higher than 220 beats per min or abnormal ventricular complexes during exercise or stress. Pharmacological cardioversion can be performed using quinidine sulphate administered orally, with an overall mean reported success rate around 80%. Other therapeutic drugs have been described such as flecainide, amiodarone or novel atrial specific compounds. Transvenous electrical cardioversion (TVEC) is performed by delivering a shock between two cardioversion catheters positioned in the left pulmonary artery and right atrium, with a success rate of >95%. After cardioversion, most horses return to their previous level of performance. However, the recurrence rate after pharmacological or electrical cardioversion is up to 39%. Recurrence has been related to previous unsuccessful treatment attempts, valvular regurgitation and the presence of atrial premature depolarisations or low atrial contractile function after cardioversion. Large atrial size and long AF duration have also been suggested as risk factors. Different approaches for preventing recurrence have been described such as the administration of sotalol, however, large clinical studies have not been published.",
keywords = "Arrhythmia, Cardiology, Equine, Quinidine, Transvenous electrical cardioversion",
author = "Annelies Decloedt and {Van Steenkiste}, Glenn and Lisse Vera and Rikke Buhl and {van Loon}, Gunther",
year = "2021",
doi = "10.1016/j.tvjl.2020.105594",
language = "English",
volume = "268",
journal = "The Veterinary Journal",
issn = "1090-0233",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Atrial fibrillation in horses Part 2

T2 - Diagnosis, treatment and prognosis

AU - Decloedt, Annelies

AU - Van Steenkiste, Glenn

AU - Vera, Lisse

AU - Buhl, Rikke

AU - van Loon, Gunther

PY - 2021

Y1 - 2021

N2 - Atrial fibrillation (AF) is suspected by an irregularly irregular rhythm during auscultation at rest and should be confirmed by electrocardiography. Heart rate monitoring is potentially interesting for AF detection by horse owners, based on the disproportionally high heart rate during exercise or increased heart rate variability. Echocardiography and laboratory analysis are useful to identify underlying cardiac disease. Horses with severe cardiac disease should not undergo cardioversion due to the risk of recurrence. Cardioversion is recommended especially in horses performing high intensity exercise or showing average maximal heart rates higher than 220 beats per min or abnormal ventricular complexes during exercise or stress. Pharmacological cardioversion can be performed using quinidine sulphate administered orally, with an overall mean reported success rate around 80%. Other therapeutic drugs have been described such as flecainide, amiodarone or novel atrial specific compounds. Transvenous electrical cardioversion (TVEC) is performed by delivering a shock between two cardioversion catheters positioned in the left pulmonary artery and right atrium, with a success rate of >95%. After cardioversion, most horses return to their previous level of performance. However, the recurrence rate after pharmacological or electrical cardioversion is up to 39%. Recurrence has been related to previous unsuccessful treatment attempts, valvular regurgitation and the presence of atrial premature depolarisations or low atrial contractile function after cardioversion. Large atrial size and long AF duration have also been suggested as risk factors. Different approaches for preventing recurrence have been described such as the administration of sotalol, however, large clinical studies have not been published.

AB - Atrial fibrillation (AF) is suspected by an irregularly irregular rhythm during auscultation at rest and should be confirmed by electrocardiography. Heart rate monitoring is potentially interesting for AF detection by horse owners, based on the disproportionally high heart rate during exercise or increased heart rate variability. Echocardiography and laboratory analysis are useful to identify underlying cardiac disease. Horses with severe cardiac disease should not undergo cardioversion due to the risk of recurrence. Cardioversion is recommended especially in horses performing high intensity exercise or showing average maximal heart rates higher than 220 beats per min or abnormal ventricular complexes during exercise or stress. Pharmacological cardioversion can be performed using quinidine sulphate administered orally, with an overall mean reported success rate around 80%. Other therapeutic drugs have been described such as flecainide, amiodarone or novel atrial specific compounds. Transvenous electrical cardioversion (TVEC) is performed by delivering a shock between two cardioversion catheters positioned in the left pulmonary artery and right atrium, with a success rate of >95%. After cardioversion, most horses return to their previous level of performance. However, the recurrence rate after pharmacological or electrical cardioversion is up to 39%. Recurrence has been related to previous unsuccessful treatment attempts, valvular regurgitation and the presence of atrial premature depolarisations or low atrial contractile function after cardioversion. Large atrial size and long AF duration have also been suggested as risk factors. Different approaches for preventing recurrence have been described such as the administration of sotalol, however, large clinical studies have not been published.

KW - Arrhythmia

KW - Cardiology

KW - Equine

KW - Quinidine

KW - Transvenous electrical cardioversion

U2 - 10.1016/j.tvjl.2020.105594

DO - 10.1016/j.tvjl.2020.105594

M3 - Journal article

C2 - 33468306

AN - SCOPUS:85098650849

VL - 268

JO - The Veterinary Journal

JF - The Veterinary Journal

SN - 1090-0233

M1 - 105594

ER -

ID: 254990881